Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib versus carboplatin + paclitaxel as first-line treatment in advanced NSCLC in Asia
jRCT2080220259Phase 3
- Sponsor
- AstraZeneca
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gefitinib in Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by AstraZeneca.
02
Drugs
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCT2080220259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220259.